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Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a multifaceted range of symptoms aﬀecting almost
every organ system. The prototypical pathology of SLE involves the production of antinuclear antibodies and the deposition
of immune complexes in basement membranes throughout the body where they induce inﬂammatory responses. The genetic
and environmental etiologies of this process are being intensively sought, and recently, TH17 cells have been implicated in the
pathogenesis of SLE. TH17 cells are CD4+ memory T cells that behave as both helper and eﬀector cell populations functioning
throughtheirsignatureIL-17cytokines.TheirdiﬀerentiationisdistincttoeithertheTH1orT H2celllineage,butstronglyinﬂuences
development of adaptive responses, including autoimmunity. This paper details the biological functions and regulation of TH17
cells, followed by an update of their expanding role in SLE.
1.Introduction
The vertebrate immune system has evolved to protect its host
against invading pathogens and other environmental anti-
gens. It is strategically organized to optimally guard against
foreign or “nonself” antigens through intricate interactions
between innate and adaptive immunity, allowing for the
survival of the host. The adaptability and resiliency of the
immune system rely on complex physiological and immuno-
logical mechanisms, many of which remain to be unraveled.
Since the initial classiﬁcation of TH1a n dT H2c e l l sb y
Coﬀman, Mosmann, and colleagues in 1986, much focus has
attempted to elucidate the role of helper T cell populations.
These eﬀorts have led to the identiﬁcation of a distinct T
helper population, called TH17 cells [1–3], which challenges
the long-standing TH1/ TH2 paradigm and has advanced our
overall understanding of T helper cells in health and disease.
Paradoxically, the same mechanisms that prevent disease
quite commonly induce hypersensitivity and autoimmunity.
In fact, it was in the study autoimmunity in which the key
observations that led to the discovery of TH17 cells were
made. These studies found that TH1 cells were not required
for induction of experimental autoimmune encephalomyeli-
tis (EAE) in mice, as had been thought [4, 5]. EAE induction
instead required an IL-23-dependent set of T cells that were
later identiﬁed as the unique TH17 cell subset. Since then,
numerous reports have shown TH17 cells to be relevant,
and sometimes central, to autoimmune pathogenesis,
highlighting them as therapeutic targets. Recently, TH17 cells
have been implicated in SLE pathogenesis. SLE is a chronic2 Arthritis
inﬂammatory disease characterized by autoantibodies to
nuclear antigens. It can be diﬃcult to diagnose and to treat
due its multifaceted nature, and death usually occurs due to
renal involvement. In this paper, we discuss the biological
function and regulation of IL-17 and TH17 cells. We will
then focus on our current understanding of the role of TH17
cells in murine and human SLE.
2.IL-17 andTH17 Cells
This subset of CD4+ memory eﬀector T cells is functionally
distinct from either the TH1o rT H2 cell lineage [6–10].
TH1 cells release mainly IFN-γ and TNF-α that regulate
cell-mediated immunity through activation of macrophages,
NK cells, and CD8+ T cells. This process is driven by IL-
12 through signal transducer and activator of transcription
4 (STAT4) activation and results in the expression of the
transcription factor T-bet. TH2 cells predominantly produce
IL-4, IL-5, and IL-13. IL-4 regulates the humoral immunity
through the activation of B lymphocytes. The process is
driven primarily by the phosphorylation of STAT6 resulting
in the activation of transcription factor GATA binding pro-
tein 3 (GATA-3). Unlike TH1a n dT H2 cells, diﬀerentiation
of TH17 cells in vitro is mediated by TCR signaling in
the presence of TGF-β and IL-6 or IL-21 stimulation [8].
Although IL-23 is not required for diﬀerentiation of TH17
cells, it is necessary for their survival and maintenance [11].
Temporal expression analysis of IL-23R indicated that it is
only expressed after activation of na¨ ıve T cells with TGF-β
and IL-6. Therefore, its expression allows for the continuous
stimulation of the diﬀerentiated cells. TH17 eﬀector cells are
characterized by the unique ability to secrete IL-17A and IL-
17F in response to stimulation by TGF-β and IL-6.
At present, there are multiple factors that are known
to contribute to the development of TH17 cells. The main
regulator of TH17 diﬀerentiation is the T-cell-speciﬁc γ
(RORγt) transcription factor induced by IL-6 and TGF-
β [12, 13]. In addition to RORγt, other transcription
factors also play critical role in TH17 cells-speciﬁc lineage
development. A recent study has indicated that IκBz works
in conjunction with RORα and RORγ in the absence
of IL-6 and TGF-β could optimally induce TH17 cell
development. Elimination of the transcriptional activation
domain as well as the ankyrin repeat domain in IκBz
would abolish its function in inducing TH17 cell formation
through the downregulation of the NF-κBp a t h w a y .I κBz
physically interacts with the noncoding sequences 2 (NCS
2) regulatory element in the Il17a promoter region to
enhance IL17a gene expression [14]. Although no speciﬁc
mechanismwasproposed,astudybySchramletal.suggested
that the activator protein (AP)-1 protein B-cell-activating
transcription factor (BATF) regulates the development of
TH17 cells by interacting with target genes downstream of
IL-6 and TGF-β signaling. These downstream genes include
the conserved intergenic elements in the Il17a-Il17f locus
and to the Il17, Il21,a n dIl22 promoters regions [15]. In
addition, another transcription factor such as IRF4 is also
involved in TH17 cell development. IRF4 is mediated by IL-
21 to physically bind with the Il17 promoter and act in
conjunction with RORγt for optimal IL-17 transcription.
IRF4 is also involved in the balance of Foxp3, RORα,a n d
RORγt during TH17 cells diﬀerentiation [16]. Furthermore,
otherfactors which belong to the Runx transcriptional factor
family member could regulate the generation of TH17 cells.
The family includes Runx 1, Runx 2, and Runx 3; however,
onlyRunx1appearstoplayamorespeciﬁcroleinpromoting
TH17 cells. An in vitro study showed that overexpression
of CD4+ T cells with Runx 1 resulted in higher IL-17
production in the presence of TGF-β alone and more
enhanced in IL-17 level when stimulated with both IL-6
and TGF-β. Therefore, the activation of RORγtb yT G F - β
alone or combination of IL-6 and TGF-β along with the
overexpression of Runx 1 allowed for optimal TH17 cells
formation. Using chromatin immunoprecipitation or ChIP
assay, the authors demonstrated that the enhanced level of
IL-17 was to due to the recruitment and synergistic binding
of RORγt and Runx 1 to the Il17 promoter and the CNS-5
enhancer region [17]. Interestingly, Foxp3 can inhibit Runx
1andR ORγttopromoteregulatoryTcells(Treg).Therefore,
thetranscriptionalregulationandthedynamicinteractionof
thesefactorsprovidemorecomplexitiesinunderstandingthe
development of TH17 cells. These interactive factors need to
be considered when attempting to categorize diﬀerent T cell
populations.
The IL-17 family of cytokines consists of six members: Il-
17A (referred to as IL-17), IL-17B, IL-17C, IL-17D, IL-17E
(IL-25), and IL-17F. Detailed descriptions of each cytokine,
in addition to IL-21 and IL-22 which are also produced by
TH17 cells, will be discussed below.
2.1.IL-17AandIL17-F. Currently,IL-17AandIL-17Farethe
best characterized cytokines within the IL-17 family. IL-17A
and IL-17F exist either as homodimers or as IL-17A/IL-17F
heterodimers [18]. Receptors for IL-17A and IL-17F include
IL-17RA and IL-17RC [19–21]. Activation of IL-17A and IL-
17F initiates powerful inﬂammatory responses and further
induces production of potent proinﬂammatory cytokines.
Both IL-17A and IL-17F can mediate the production of
IL-6, CCL3, and G-CSF in macrophages, but only IL-17A
can activate CCL2, IL-1β, IL-12p70, and IL-9. IL-17A is
also solely responsible for the activation of CCL2, CCL3,
GM-CSF, IL-1β, and IL-9 in CD4+ T cells [22]. As part of the
local inﬂammatory response, both cytokines are responsible
for the proliferation, maturation, and recruitment of
neutrophils [1]. They provide immediate immunological
protection by producing antimicrobial and acute phase
response proteins against a variety of pathogens, speciﬁcally
Propionibacterium acnes, Citrobacter rodentium, Klebsiella
pneumoniae, Bacteroides spp., Staphylococcus aureus [23],
acid-fast Mycobacterium tuberculosis, and fungi infection
such as Candida albicans [18, 24].
Most importantly, having the potential to upregulate the
expression of speciﬁcs matrix metalloproteinases (MMPs)
such as MMP-1, MMP-3, MMP-9, MMP-13, IL-17A, and IL-
17F have been shown to be tissue-damaging cytokines and
areintimatelyinvolvedinautoimmunediseases,forexample,
Crohn’s disease [25, 26], EAE [4], collagen-induced arthritis
(CIA) [5], Sj¨ ogren’s syndrome (SjS) [27, 28]a n dS L Ew h i c hArthritis 3
will be later discussed [29–34]. However, a recent study
by Ishigame et al. [23] suggested that there are diﬀerential
roles for IL-17A and IL-17F in autoimmune responses, in
which IL-17F played a minimal role in the pathogenesis of
delayed-type and contact hypersensitivities, EAE, CIA, and
arthritis in animal models. In contrast, IL-17A appeared to
produce more potent pathogenic cytokines in macrophages,
whereby genetic knockout of il-17a rendered the mice with
reduced disease phenotypes. The diﬀerential role of IL-
17A and IL-17F raises interesting questions in deciphering
mucosal immunity and autoimmunity. Both cytokines elicit
their responses via similar receptor complexes; however, it is
intriguing that they provide diﬀerent autoimmune responses
in terms of pathogenicity and protection. The contrasting
biological functions could be due to an approximate 10-fold
more potent induction of cytokines by IL-17A as compared
to IL-17F [35] .I ns u p p o r to ft h i sc o n c e p t ,ar e c e n tr e v i e w
by Dubin and Kolls [36]h a ss u g g e s t e dam o d e lw h i c h
emphasizes the bioactivities of these cytokines on myeloid
versus nonmyeloid cells or macrophages versus CD4+ T cells
discussed priorly. Therefore, it is the ability of IL-17A to
induce stronger responses and aﬀect a wider range of cellular
targets, making it a more pathogenic cytokine. It will be of
interest if such a dichotomy is seen in SLE.
2.2. IL-17B, IL-17C, and IL-17D. IL-17B, IL-17C, and IL-
17DaretheleaststudiedmembersoftheIL-17cytokinefam-
ily. It remains speculative whether they are capable of elicit-
ing any proinﬂammatory or protective responses like IL-17A
and IL17F. A study using the CIA mouse model has shown
that adoptive transfer of IL-17B+ or IL-17C+ CD4+ T cells
was able to recapitulate a CIA phenotype and that blockade
of IL-17B prevented disease exacerbation. The authors sug-
gested that the inﬂammation induced by IL-17B/IL-17C is
mediatedbytheproductionofTNF-α[37].However,genetic
association study in coeliac disease (CD) using large sample
of patients and controls (409 CD, 355 controls) provided no
conclusiveevidenceintheassociationofthegeneticvariation
of a number of cytokines including IL-17B and the develop-
ment of the disease [38]. Interestingly, our recent microarray
data from the C57BL/6.NOD-Aec1Aec2 mouse model of
primary-SSrevealedastrongupregulatedexpressionofIl17b,
thus, this cytokine may play an important but unidentiﬁed
role in the rheumatic diseases (unpublished data).
2.3. IL-17E (IL-25). Designated as IL-25, IL-17E has been
shown to induce TH2-like responses with the upregulation
of IL-4, IL-5, and IL-13 gene expression [39]. Furthermore,
the ability of IL-17E to promote the expression of adhesion
molecules, speciﬁcally ICAM-1, ICAM-3, and L-selectin,
allows for eosinophilic inﬁltration and structural changes of
epithelial cells, making it a vital cytokine for allergic inﬂam-
matory response and/or asthma-related attacks [40]. Acti-
vation of TH2-related cytokines also resulted in signiﬁcant
elevation of IgE, IgG1, and IgA levels in which IgE can induce
the release of prostaglandin D2 (PGD2) on mast cells that
directly mediates the vasodilatation, mucus production, and
broncho-constriction. While IL-17E is normally negatively
regulated by a Socs3-dependent pathway [41], numerous
approaches have attempted to inhibit the biological function
of IL-17E. Administration of monoclonal antibody that
blocked the function of IL-17E dramatically reduced the
production of IL-5/IL-13, inﬁltration of eosinophils, and
IgE secretion, thereby preventing the antigen-driven airway
inﬂammation and airway hyperresponsiveness (AHR) [42].
Taking advantage of the ability of IL-17E to bind to IL-17RA
and IL-17RB receptors, antagonist monoclonal antibodies
against either IL-17RB or IL-17RA receptor resulted in com-
plete abolishment of IL-17E-induced AHR in na¨ ıve BALB/C
mice [43]. A better understanding of IL-17E has shed addi-
tional information on the immunological activities of IL-
17E cytokine and its participation in allergic inﬂammation,
therebyproviding potential therapeutictargets. Interestingly,
a recent study by Kleinschek et al. [44] has indicated that
IL-17E might play an opposing role to IL-17A. Knocking
out IL-25 rendered the animals highly susceptible to the
development of EAE characterized by the increase of IL-23
level and inﬁltration of IL-17 and IFN-γ producing T cells
in the central nervous system. Furthermore, neutralization
of IL-17A in the knockout mice prevented EAE [44]. This
data clearly suggests the inhibitory role of IL-17E in EAE.
However, genetic association study in patients with Crohn’s
disease or ulcerative colitis concluded that IL-17E has little
association in the disease development [45]. Consequently,
extensive studies are needed to fully elucidate the role of IL-
17E in human disease.
2.4.IL-21andIL-22. Inadditiontotheirsignaturecytokines,
TH17 cells also produce IL-21 and IL-22. IL-21 functions
as an autocrine cytokine which allows for an alternative
diﬀerentiation pathway for TH17 cells when IL-6 is absent
[46]. Furthermore, IL-21 is involved in the ampliﬁcation
of TH17 cell-speciﬁc lineage transcription factors allowing
for the maintenance and stabilization of this cell population
[16, 47]. IL-21 is also known to assist the activation and
diﬀerentiationofna¨ ıveBcellstoplasmacellsbyupregulation
of Blimp-1 [48]. In addition, it induces the expression of
the γ1a n dγ3 germline transcripts for the isotypic switching
to IgG1 and IgG3 from IgMin human B cells [49]. These
features, thereby, establish IL-17-producing cells as helper T
cells. The isotypic switching potential of IL-21 is critical in
modulating the disease development of isotypic-dependent
autoimmune diseases such as SLE [50]a n dS j S[ 28, 51–
54]. In the nonobese diabetic (NOD) animal model for
SjS, isotypic switching to an IgG1 antibody against the
acetylcholine receptors (AchRs), speciﬁcally the muscarinic
receptor type 3 (M3R), is required for the development
of SjS. Perhaps, the most critical is its involvement in the
formation of germinal centers by controlling the expression
ofBcl-6,whichregulatesthesurvivalandactivationofBcells.
Furthermore, IL-21 is necessary for the expansion of TH17
cells and follicular T helper cells through the costimulatory
ICOS and c-Maf pathway [55]. Therefore, it is a critical
cytokine in modulating not only the T cell biology, but also
the B cell response.
IL-22 is a cytokine that is produced by subsets of TH17
cells as well as a multitude of other cell types, including
natural killer cells-22 (NK-22), lymphoid tissue inducer4 Arthritis
(LTi) cells, and epithelial cells. Mucosal microﬂora can
promote the secretion of IL-22 from epithelia and the
diﬀerentiation of IL-22-producing cell populations, in par-
ticular cell populations expressing NKp46, for example, the
RORγt+CD3−NKp46+ NK cell, the RORγt+CD3−NKp46−
LTi cell, and an uncharacterized RORγt+CD3+NKp46+ cell
population. The IL-22 receptor complex is a heterodimeric
molecule composed of IL-22RA1 and IL-10R2 [56]. On
interacting with its heterodimeric receptor (IL-10R2/IL-
22R), IL-22 can transduce a signal through phosphorylation
of tyrosine kinases Jak1 and Tyk2, followed by the
activation of STAT3, and to a lesser degree a heterodimeric
STAT1/STAT3 during signaling cascade [57]. IL-22 has also
been reported to activate several signaling pathways, includ-
ing the MAPK pathway via ERK1/2, JNK, and p38 for induc-
tion of IL-22-related genes [58]. Since epithelial cells express
high levels of IL-10R2 and IL-22R, IL-22 can initiate a strong
response from epithelial cells which includes production of
cytokines, chemokines, acute phase proteins, and a number
of antimicrobial molecules such as β-defensin, lipocalins,
and calcium binding S100 proteins [59]. It is also involved in
tissue repair following exacerbated immune responses and
epithelial-barrier functions against bacterial infections [60].
Paradoxically, IL-22 has been shown to be pathogenically
associated with several autoimmune diseases including
rheumatoid arthritis [61] and Crohn’s disease [62]a sw e l l
as non-autoimmune diseases such as respiratory-distress
syndrome [63] and cystic ﬁbrosis [64]. Whether IL-22 is an
important player in development and/or onset of rheumatic
disease, like SLE, will be an interesting area of future
studies.
3. Negative Regulation of TH17 Cells
It remains controversial whether TH17 cells are protective or
pathogenic. Its mode of response is substantially dependent
on the eliciting antigenic entities. In certain cases of fungal
andbacterial infections, IL-17canbe protective by recruiting
neutrophils to the site of injury; however, IL-17 activation
can also lead to rampant and impetuous immune response
resulting in exacerbated clinical pathology and autoim-
munity. Therefore, regulatory elements of the IL-17/TH17
system are required to maintain congruency and homeosta-
sis between the protective and pathogenic consequences.
Although the research area is still in its infancy, as of present,
there are clearly multiple systems that have the capability
to regulate the development and diﬀerentiation of TH17
cells. One of the most critical regulatory factors is the IL-
27 cytokine, which is secreted by activated macrophages and
dendritic cells [65]. IL-27 is a member of the IL-12 family of
cytokines and is comprised of a heterodimer between IL-27α
(IL-27 p28) and IL-27β (IL-27 Ebi3) [66]. IL-27 (or the IL-
27 p28 subunit per se) exerts the IL-27-associated biological
eﬀects by activating its heterodimeric IL-27R including
WSX-1 and gp130. Signal transduction involves phosphory-
lation of JAK1, JAK2, STAT1, STAT3, STAT4, and STAT5 in T
cells, NK cells, and monocytes, but only STAT3 in mast cells
[67]. However, only STAT1 or STAT3 activation is critical for
the resulting bioactivity of IL-27 on na¨ ıve T cells that express
IL-27R [68]. Activation of STAT1 by JAK1 or JAK2 promotes
TH1d i ﬀerentiation via the upregulation of T-bet resulting in
the production of IFN-γ. At the same time, IL-27 inhibits
the production of IL-2 and IL-6, thus downregulating the
IL-6-dependent STAT3 activation of RORγt expression and
subsequent development of TH17 cells. Recent studies have
suggested that IL-27 is pleiotropic, regulating hematopoietic
stem cell diﬀerentiation, eliciting antitumor activities, as well
as promoting both pro- and anti-inﬂammatory activities
[69–72].Duetoitspotentsuppressiveability,IL-27functions
to inhibit the diﬀerentiation of TH17 cells in both in
vitro and in vivo studies. In several animal models of
autoimmune diseases, a deﬁciency in either IL-27 or IL-27R
results in exacerbated pathology and clinical signs mainly
due to the dysregulation and increase in numbers of IL-
17 producing T cells [11]. Additionally, systemic injection
of rIL-27 cytokine into autoimmune animal models of
EAE, scleritis, or uveitis ameliorates many clinical symptoms
[73]. Thus, the TH17/IL-23/IL-27 system is thought to
bridge innate immunity and subsequent adaptive immune
responses.
In addition to IL-27, other T helper cells populations can
also negatively regulate the development of TH17 cells. As
mentioned earlier, IFN-γ produced by TH1 cells upregulates
the T-bet transcriptional factor which dampens the activa-
tion of RORγt resulting in the downregulation of TH17 cells.
Similarly, the upregulation of GATA-3 transcription factor of
TH2 cells by IL-4/5/13 could also restrict the expansion of
TH17 cells by inhibiting the function of RORγt. One major
aspect of TH17 cells negative regulation is the inﬂuence
of Treg cells. Treg cell diﬀerentiation is driven mainly by
TGF-β which activates Foxp3. Sharing the ubiquitous TGF-
β factor, the presence or absence of IL-6 controls the
developmental shift toward TH17 or Treg cells. The shift to
CD4+CD25+Foxp3+ Treg and CD4+CD25+Foxp3+CD39+
subset plays a signiﬁcant role in restricting the detrimental
eﬀect of TH17 cells in multiple sclerosis patients [74].
Interestingly, retinoic acid increases the expression of Foxp3
via activation and phosphorylation of Smad3 and concomi-
tantly inhibits the expression of IL-6Rα,I R F - 4 ,a n dI L - 2 3 R ,
thereby limiting TH17 development [75]. An exciting and
confounding feature of TH17 development is the plasticity
among diﬀerent T helper cells populations and the microen-
vironment or microﬂora that imposes on its lineage-speciﬁc
diﬀerentiation. A study by Koenen et al. has demonstrated
that human CD25highFoxp3+ Treg cells when stimulated
with allogeneic monocytes in the presence of IL-2 and IL-
15 can diﬀerentiate into IL-17 producing T cells. The study
further showed that the lateral lineage conversion to TH17
cells from Treg cells relied on the histone deacetylase activity
indicating the contribution of epigenetic modiﬁcation [76].
In addition, TH17 cells have the propensity to convert to
TH17/TH1 phenotype under the appropriate milieu of low
TGF-β and high IL-12 levels which are often observed in
thejoints of children withinﬂammatoryarthritis [77].Other
microorganisms such as live C. albicans can modulate tryp-
tophan metabolism to inhibit IL-17 production [78], and H.
pylorimediatesthepolarizationofTH17/Tregbalancetoward
regulatory response which inhibits TH17 response [79].Arthritis 5
4.IL-17inMurineLupus
As previously mentioned, the role of TH17 in the develop-
ment of autoimmunity was initially scrutinized in murine
modelsofinducedEAE[2].Thisdiseasemodelwasoriginally
believed to be dependent on IL-12, and thus, TH1 mediated.
However, the revelation that IL-12 shared a subunit, p40,
with a newly discovered cytokine, IL-23, and that this novel
cytokine,notIL-12,wasrequiredforinductionofdiseasesets
the stage for investigation of TH17 these models [4, 5]. More
recently, several lines of research have reported increased
IL-17 production and TH17 functions in murine models of
lupus as summarized in Table 1.
BXD2 is one of 20 BXD recombinant inbred strains
derived from a cross between C57BL/6J (B6) and DBA/2J.
Thesemicedevelopaspontaneousandage-dependentlupus-
like syndrome denoted by production of the canonical anti-
DNA, antihistone, and rheumatoid factor autoantibodies, as
well as splenomegaly, glomerulonephritis (GN), and erosive
arthritis [80, 81]. BXD2 CD4+ T cells have enhanced TH17
development and consequent increased serum levels of IL-17
[82]. Moreover, IL-17-secreting CD4+ cells were shown to
localize to germinal centers (GCs) in BXD2 spleens. This
augmented IL-17 response was associated with increased GC
development and stability in BXD2 spleens as compared to
B6 controls. Additionally, BXD2 have increased amounts of
I L - 1 7 R +Bc e l l s[ 82] .T h e s eBc e l l sh a v eb o t ha ni n c r e a s e d
basal and an IL-17R-induced activation of the canonical
NFκβ pathway, resulting in an increased expression of
regulator of G signaling (RGS) proteins [83]. Consequently,
RGSs enhance the GTPase activity of chemokine receptor
Gα subunits resulting in decreased chemotaxis [84, 85].
Indeed, BXD2 B cells were shown to have a diminished
chemotactic response to CXCL12 and CXCL13, especially
in the presence of IL-17 [82, 83]. This increased potential
for B cell accumulation at the sites of CXCL12 and CXCL13
production, such as follicular dendritic cell rich areas
[86, 87], is the likely cause of the enhanced GC formation
in the BDX2 strain. Moreover, the concurrent production
of IL-17 by TH17 cells in GCs further promotes B cell
accumulation and GC stability. IL-17 also results in
increased activation-induced cytidine deaminase (Aicda)
expression and somatic hypermutation in BXD2 IL-17R+ B
cells, which have an intrinsically enhanced ability to produce
autoantibodies as compared to IL-17R-deﬁcient BDX2 B
cells [82]. Thus IL-17 has a central role in pathogenesis of
the lupus-like syndrome observed in this model.
The MRL/lpr strain is a classical model of spontaneous
lupus. It exhibits a lymphoproliferative disorder which
manifests with autoantibody production, GN, and accumu-
lation of CD4−CD8− double-negative T (DNT) cells in the
periphery [88]. A mutation in Fas is responsible for the
lpr phenotype and is the major functional contributor of
pathogenesis in this strain [89, 90]. It was recently shown
that Fas-deﬁcient DNT cells are capable of producing sig-
niﬁcant amounts of IL-17 [91]. Further, the TH17-stablizing
cytokine, IL-23, potently induced IL-17 production in these
DNT cells which were then capable of renal inﬁltration
and GN induction. Finally, deletion of IL-23R prevented
Table 1: IL-17 in murine models of lupus.
Model Description References
BXD2
IL-17 promotes spontaneous GC
development as well as autoantibody
production by IL-17R+ Bc e l l s
[82, 83]
MRL.lpr
Expansion of IL-17-producing DNT cells
with kidney inﬁltration and GN
induction
[91, 92]
SNF1 Enhanced IL-17 production by CD4+ T
cells with kidney inﬁltration [94]
NZM2328 Disruption of TNFα promotes Th17
development [97]
splenomegaly, lymphadenopathy, autoantibody production,
and GN in the context of Fas deﬁciency and was associated
with a major reduction of the DNT cell compartment
along with its concomitant IL-17 production [92]. Thus,
a pathogenic TH17-like function of DNT cells has been
exposed, highlighting this subset as a target for disease
intervention.
The SNF1 mouse model, derived from the F1 outcross of
theNewZealandBlackandSWRrecombinantinbredstrains,
develops a spontaneous lupus-like syndrome that can be
accelerated by immunization of nucleosomal peptides [93].
Upon disease induction, autoantibodies are produced, and
GNwithTH17inﬁltrationisinitiated[94].Interestingly,low-
dose therapy of a tolerogenic histone-derived peptide caused
increased TGF-β and decreased IL-6 expression in dendritic
cells and resulted in enhancement of Treg function with
ar e d u c t i o ni nT H17 renal inﬁltrates [94]. Treatment with
either oral or nasal anti-CD3 also ameliorates autoantibody
production and nephritis in this model by inducing a
regulatory T cell subset and reducing IL-17 production by
T follicular helper cells [95, 96]. These results indicate that
therapies that regulate Treg/TH17 homeostasis in favor of
Treg might be eﬀective at moderating SLE pathogenesis.
Finally, disruption of TNFα receptor signaling in spon-
taneous lupus-prone NZM2328 mice results in exacerbated
disease that has associated with a greatly enhanced T
eﬀector/memory compartment. These cells were found to
have a Th17 gene signature and produced more IL-17 than
TNF-α receptor suﬃcient T eﬀector/memory cells [97]. This
work highlights the regulatory function that TNF-α can have
and sets a caution for TNF-α blockade therapy.
5. IL-17 inSLE Patients
As with murine lupus models, evidence for a TH17 role
in human SLE is also mounting. Several recent reports
show that plasma IL-17 and IL-17 producing T cells are
increased in SLE patients [29–34]. Moreover, disease activity
and severity are associated with increased IL-17 production
[31–34]. SLE patients have increased phosphorylation of
STAT3 [98], which is required for TH17 diﬀerentiation, as
STAT3 deﬁciency in hyper-IgE syndrome patients results in
the ablation of TH17 cells [99, 100]. The TH17-polarizing6 Arthritis
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Figure 1: IL-17 in SLE pathogenesis. IL-17, IL-21, and BAFF promote survival, class-switching, and production of antinuclear
autoantibodies by autoreactive B cells. Consequently, nucleic acid-containing immune complexes stimulate plasmacytoid dendritic cells
(pDCs) to produce type I interferon, IL-6, and IL-23, which enhance DC activation, and TH17 induction, thus completing a feedback loop
forautoimmuneactivation. Concurrently,hyperactivation inthecontext ofautoimmunitymayactuatetheaccumulation ofdouble-negative
T (DNT) cells which produce more IL-17 and exacerbates the disease state. Ultimately, TH17 and DNT cells inﬁltrate systemic tissues and
incite end organ disease.
cytokines, IL-6, IL-21, and IL-23, all signal in a STAT3-
dependent manner to induce transcription of the RORγt
[101]. Indeed, SLE patients also have increased plasma levels
of IL-6, and higher Rorc expression, which encodes RORγt
[34, 102]. Taken together, TH17 expansion is an important
feature of SLE that needs to be further investigated.
It is well established that there is a strong gender bias
in the incidence of SLE in which roughly 90% of the cases
occur in females. Since IL-17 production correlates with
disease severity, the question is raised as to whether the
female bias of SLE is due to diﬀerences in TH17 biology.
While this has not been studied extensively, IL-17 in vitro
production was shown to decrease with age in males, but
not in females [103]. Although these results do demonstrate
ag e n d e rd i ﬀerence, the relevance to SLE induction is not
clear since the young cohorts, who were between 21 and 40
years old, the highly susceptible age of onset for SLE, did not
produce diﬀerent amounts of IL-17 in males versus females.
Nevertheless, the ability to maintain higher levels of IL-17
production with age may contribute to the maintenance of
the disease state in females. More recently, it was reported
that in vivo treatment of mice with estrogen enhances TH17
polarization in vitro, supporting the hypothesis that TH17
cells contribute to the female bias of SLE [104]. There is,
however, no direct evidence for this hypothesis, and further
study is needed to clarify the role that gender may play in
TH17 function and disease induction.
Similar to Fas-deﬁcient mouse models of lupus, a
signiﬁcant amount of IL-17 is also produced by an expanded
subset of DNT cells in SLE patients [30]. These DNT cells
are derived from CD8+ cells that have downregulated CD8 in
response to receptor stimulation [105]. While they are nor-
mally present in very small amounts, their expansion in SLE
patients may be due to increased T cell activation. Because of
their downregulated coreceptor, they have decreased survival
and proliferation and display unique gene expression pat-
terns and proinﬂammatory cytokine proﬁles [105]. Notably,
as in lupus-prone mice, DNT cells can be found in kidney
biopsies of SLE patients [30]. Therefore, DNT cells appear
to represent a distinct eﬀector population of T cells whose
dysregulation may be central to SLE pathogenesis.
The fundamental role of type I IFN dysregulation is well
established in SLE pathogenesis [106]. Unregulated IFN-
α production has been shown to increase proinﬂamma-
tory cytokine production, including IL-6 and IL-23 which
lead to Th17-mediated inﬂammation in mice [107]. Also
plasmacytoid dendritic cells (pDCs), which are known to
potently secrete IFN-α, also produce IL-1β, IL-6, and IL-
23 in response to Toll-like receptor (TLR)-7 stimulation
in human studies [108, 109]. These pDCs are capable ofArthritis 7
inducing TH17 diﬀerentiation when cocultured with CD4+
cells. Endogenous nucleic acids are autoantibody targets in
SLE and are capable of TLR activation following their uptake
as immune complexes [110, 111]. Therefore, pDCs can be
chronically activated, potentiating Th17 development and
disease pathogenesis.
IL-17 also promotes B cell survival both alone and
synergistically with B cell-activating factor (BAFF) [31].
Hence, a feedback loop is established where IL-17 pro-
motes autoreactive B cells to persist longer and make
autoantibodies which activate pDCs induce more TH17
cells. In parallel, the expansion of DNT cells results in more
IL-17 production, exacerbating this progression (Figure 1).
As IL-17 is central mediator to this process, therapeutic
intervention that targets TH17 development and IL-17
production will be valuable treatments for SLE.
6. Conclusions
The discovery of IL-17 and TH17 cells has expanded and
transformed the conventional thought in immunology. The
change adds complexity to an already complicated matter.
The intricate and dynamic interaction between the diﬀerent
characters promotes the adaptability and resiliency of the
immune system. Therefore, it is diﬃcult to comprehend that
any one particular entity is solely responsible for such a
vexing system. The coincidental discovery of TH17 cells did
not shift any paradigms, but merely add another unknown
factor to an unsolved equation. Currently, there are numbers
ofissuesthatneedtoberesolved,forexample,thediﬀerential
function of IL-17 molecules within the family in the
context of infectious disease and autoimmunity, the negative
regulation of TH17 cells and its application in therapeutic
approach, and its relevance in the pathogenesis of SLE
besides observational or correlative studies. Tremendous
strides are being made to address these issues.
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